"AF, it sounds like you suffer from PTSD."
Hahaha - nail on the head. The last ADCOM was a complete horror show. I was all in having watched it fall from the 19's to around 7 and was expecting a positive vote and a swing back up. It went to under $1 instead. I averaged down to about $3 and went all in again in the run-up to the R-IT results. Sold about half then in the high $17's and planned to use the cash to trade around the core but my interpretation of the TA suggested that there was a very high chance it would drop back down to the low teens at least so sold the rest.
After being through all that "anxiety to be right" doesn't bother me. I still say it drops back down near term along with the main indexes but don't have any problem buying back in the $20s IF it closes above $23 and holds the gains. I have it on good authority that the best traders on Wall St are correct only 60% of the time. The main difference between them and retail traders, as im sure you well know, is that they know how to manage risk and when to cut their losses on losing trades. Someone on here had mentioned a company called Novavax a few weeks ago and I saw that the share price cratered yesterday on a failed Ph3 trial. The 13k's for Q4 2018 show that Blackrock held 32M shares, Vanguard 21M, and State Street nearly 15M. Blackrock's fund value is nearly $2 Trillion, Vanguard's is just over $2 Trillion,and State Street $1 Trillion. The Baker Bros are not immune to getting it wrong from time to time either.
I agree with your sentiments re an ADCOM but my PTSD wont allow be to go all in this time round. No reason whatsoever why it shouldnt be a landslide vote in favour of approval because a) The drug works and b) It's safe. You can never be 100% certain though.
Any thoughts on Amarin's valuation? Do you see the share price continuing to rise from now until an ADCOM assuming there is no BO offer? I dont personally but as I mentioned, if it breaks $23 and holds ill have to concede that it more than likely will continue to rise.
